Michael Celano - 26 Jan 2026 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Reporting relationship: Chief Financial Officer
Issuer ticker: LRMR
Reported as of: 26 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jan 2026, 17:03:39 UTC
Prior SEC filing: 24 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Johansson, Attorney-in-fact

Key filing fact

Michael Celano filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 27 Jan 2026.

Key facts

This page summarizes Michael Celano's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Jan 2026, 17:03.

Change

Previous filing in this sequence was filed on 24 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001377582 Primary reporting owner

Celano Michael

Relationship: Chief Financial Officer
Address: C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST, SUITE 506, BALA CYNWYD
Signature: /s/ Jennifer Johansson, Attorney-in-fact
Signature date: 27 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LRMR transaction

Common Stock

Award

Transaction value: $0
Shares: +37,604
Change %: +21%
Price: $0.000000
Shares after: 215,785
Date: 26 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LRMR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +225,622
Change %
Price: $0.000000
Shares after: 225,622
Date: 26 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 225,622
Exercise price: $3.60
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

Footnote F2

The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.